The Allergenic Role of the Drug Excipient in a Case of Allergy in Pcsk-9 Inhibitor

Hyperlipidemia is a well-established risk factor for the development of cardiovascular disease (CVD) [1]. Proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors are novel drugs in use against hyperlipidemia [2]. The gene for this enzyme is encoded by the PCSK9 gene that is located on chromosome 1. This gene contains one of 27 loci associated with increased risk of coronary artery disease [3, 4]. PCSK-9 is expressed in many tissues and it has the ability to bind to low-density lipoprotein receptor (LDL-R) and to reduce its number on the extracellular side of cell membranes. This results in a decreased ability of the cells to uptake low-density lipoprotein (LDL) and in this way, in a higher concentration of LDL in blood circulation [5]. Therefore, blocking PCSK-9 can lower blood LDL concentrations thus having an important medical importance [6]. We present a case of allergy on Alirocumab only, one of PCSK-9 inhibitors.